Thomas Moehler

2.9k total citations
69 papers, 2.1k citations indexed

About

Thomas Moehler is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Thomas Moehler has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Hematology, 30 papers in Molecular Biology and 24 papers in Oncology. Recurrent topics in Thomas Moehler's work include Multiple Myeloma Research and Treatments (54 papers), Cancer Treatment and Pharmacology (16 papers) and Protein Degradation and Inhibitors (10 papers). Thomas Moehler is often cited by papers focused on Multiple Myeloma Research and Treatments (54 papers), Cancer Treatment and Pharmacology (16 papers) and Protein Degradation and Inhibitors (10 papers). Thomas Moehler collaborates with scholars based in Germany, France and United States. Thomas Moehler's co-authors include Hartmut Goldschmidt, Anthony D. Ho, Kai Neben, Jens Hillengaß, Gerlinde Egerer, Axel Benner, Stefan Delorme, Hans‐Ulrich Kauczor, Alwin Kraemer and Dirk Hose and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Thomas Moehler

68 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Moehler Germany 25 1.4k 1.1k 739 281 253 69 2.1k
Parameswaran Venugopal United States 21 1.1k 0.8× 684 0.7× 412 0.6× 482 1.7× 98 0.4× 130 1.9k
Annamaria Brioli Italy 20 1.8k 1.3× 1.3k 1.3× 954 1.3× 255 0.9× 181 0.7× 72 2.2k
Rudolf Schlag Germany 16 973 0.7× 871 0.8× 1.0k 1.4× 808 2.9× 145 0.6× 60 2.3k
Konstantinos Zervas Greece 21 1.4k 1.0× 937 0.9× 1.2k 1.7× 475 1.7× 88 0.3× 61 2.2k
Margaret Macro France 24 1.7k 1.2× 1.4k 1.4× 1.8k 2.5× 720 2.6× 210 0.8× 83 3.6k
Sherry Pierce United States 36 3.5k 2.6× 1.8k 1.7× 897 1.2× 1.3k 4.7× 42 0.2× 131 4.5k
Álvaro Aguayo Mexico 19 867 0.6× 933 0.9× 506 0.7× 501 1.8× 36 0.1× 46 1.8k
María Eugenia Sarasquete Spain 26 837 0.6× 971 0.9× 608 0.8× 401 1.4× 70 0.3× 80 1.9k
Kay Delasalle United States 31 2.6k 1.9× 1.7k 1.6× 1.6k 2.1× 953 3.4× 62 0.2× 61 3.4k
Nora Viniou Greece 15 546 0.4× 339 0.3× 489 0.7× 321 1.1× 99 0.4× 43 1.1k

Countries citing papers authored by Thomas Moehler

Since Specialization
Citations

This map shows the geographic impact of Thomas Moehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Moehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Moehler more than expected).

Fields of papers citing papers by Thomas Moehler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Moehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Moehler. The network helps show where Thomas Moehler may publish in the future.

Co-authorship network of co-authors of Thomas Moehler

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Moehler. A scholar is included among the top collaborators of Thomas Moehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Moehler. Thomas Moehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Müller, Marc, et al.. (2023). 844P Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models. Annals of Oncology. 34. S550–S550. 1 indexed citations
2.
Schmitt, Stefan, Thomas Hielscher, Claudia D. Baldus, et al.. (2013). Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation. International Journal of Hematology. 97(6). 765–772. 2 indexed citations
3.
Hillengaß, Jens, Maximilian Merz, Hartmut Goldschmidt, et al.. (2013). Prognostic Significance Of Parameters Of Dynamic Contrast-Enhanced MRI Detecting Increased Bone Marrow Microcirculation In Monoclonal Plasma Cell Disorders. Blood. 122(21). 3146–3146. 2 indexed citations
4.
Moehler, Thomas. (2012). Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma. Current Cancer Drug Targets. 12(4). 372–390. 10 indexed citations
5.
Moehler, Thomas & Hartmut Goldschmidt. (2011). Therapy of Relapsed and Refractory Multiple Myeloma. Recent results in cancer research. 183. 239–271. 15 indexed citations
6.
Hillengaß, Jens, Thomas Moehler, & Michael Hundemer. (2011). Monoclonal Gammopathy and Smoldering Multiple Myeloma: Diagnosis, Staging, Prognosis, Management. Recent results in cancer research. 183. 113–131. 5 indexed citations
7.
Hillengaß, Jens, Kerstin Fechtner, Marc‐An dré Weber, et al.. (2010). Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma. Journal of Clinical Oncology. 28(9). 1606–1610. 255 indexed citations
8.
Bäuerle, Tobias, Jens Hillengaß, Kerstin Fechtner, et al.. (2009). Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging. Radiology. 252(2). 477–485. 87 indexed citations
9.
Hillengaß, Jens, Anthony D. Ho, Hartmut Goldschmidt, R. Waldherr, & Thomas Moehler. (2008). Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis. International Journal of Hematology. 88(4). 454–456. 2 indexed citations
10.
Condomines, Maud, Dirk Hose, P Raynaud, et al.. (2007). Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis. The Journal of Immunology. 178(5). 3307–3315. 96 indexed citations
11.
Früehauf, Stefan, Johannes Huesing, Marlon R. Veldwijk, et al.. (2007). Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplantation. 39(12). 743–750. 36 indexed citations
12.
Herrmann, Doris, Iris Breitkreutz, Ute Hegenbart, et al.. (2006). Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. European Journal Of Haematology. 78(1). 21–28. 48 indexed citations
13.
Moehler, Thomas, Jens Hillengaß, Axel Glasmacher, & Hartmut Goldschmidt. (2006). Thalidomide in Multiple Myeloma. Current Pharmaceutical Biotechnology. 7(6). 431–440. 13 indexed citations
14.
Wasser, K., Thomas Moehler, Christina G. Rehm, et al.. (2005). Korrelation zwischen MRT und Histopathologie des Knochenmarks bei Patienten mit Multiplem Myelom. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 177(8). 1116–1122. 18 indexed citations
15.
Witzens‐Harig, Mathias, Thomas Moehler, Kai Neben, et al.. (2004). Development of leukocytoclastic vasculitis in a patient with multiple myeloma during treatment with thalidomide. Annals of Hematology. 83(7). 467–470. 6 indexed citations
16.
Schlenzka, Jana, Thomas Moehler, Sergey M. Kipriyanov, et al.. (2004). Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anti-Cancer Drugs. 15(9). 915–919. 18 indexed citations
17.
Gerull, Sabine, Ute Hegenbart, Martin Göerner, et al.. (2004). Non-Myeloablative Allogeneic Transplantation in Patients with Relapsed or Refractory Multiple Myeloma.. Blood. 104(11). 2759–2759. 1 indexed citations
18.
Neben, Kai, Joannis Mytilineos, Thomas Moehler, et al.. (2002). Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 100(6). 2263–2265. 68 indexed citations
19.
Moehler, Thomas, H. Hawighorst, Kai Neben, et al.. (2000). Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom. Der Radiologe. 40(8). 723–730. 7 indexed citations
20.
Hawighorst, H., et al.. (1999). Evaluation of angiogenesis and perfusion of bone marrow lesions: Role of semiquantitative and quantitative dynamic MRI. Journal of Magnetic Resonance Imaging. 10(3). 286–294. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Parameswaran Venugopal Breakdown of academic impact, for papers by Annamaria Brioli Breakdown of academic impact, for papers by Rudolf Schlag Breakdown of academic impact, for papers by Konstantinos Zervas Breakdown of academic impact, for papers by Margaret Macro Breakdown of academic impact, for papers by Sherry Pierce Breakdown of academic impact, for papers by Álvaro Aguayo Breakdown of academic impact, for papers by María Eugenia Sarasquete Breakdown of academic impact, for papers by Kay Delasalle Breakdown of academic impact, for papers by Nora Viniou
Rankless by CCL
2026